Dr. Alan Kivitz, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Albany Medical College of Union University (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,014
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: Albany Medical College of Union University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
PA license MD026744E
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Altoona Altoona, PA
- Penn Highlands Dubois Dubois, PA
- Conemaugh Memorial Medical Center Johnstown, PA
- Indiana Regional Medical Center Indiana, PA
- UPMC Bedford Memorial Everett, PA
Medical groups
- Phoenix Rehabilitation and Health Services Inc (2,800 clinicians)
- Keystone Rehabilitation Systems Inc (776 clinicians)
- Vantage Physical Therapy and Rehabilitation Inc (260 clinicians)
- Alan J Kivitz MD PC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,014
- Services billed
- 245,324
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 97,200 | 41 |
| Injection, tocilizumab, 1 mg | 70,313 | 18 |
| Injection, golimumab, 1 mg, for intravenous use | 23,464 | 33 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12,925 | 24 |
| Injection, denosumab, 1 mg | 7,800 | 87 |
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 1,888 | 22 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,790 | 881 |
| Insertion of needle into vein for collection of blood sample | 1,635 | 841 |
| Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | 1,560 | 24 |
| Liver enzyme (sgot), level | 1,554 | 759 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 31 companies reported 540 payments worth $105,010 in total to this clinician.
| AbbVie Inc. | $46,405 |
|---|---|
| UCB, Inc. | $23,391 |
| Tonix Medicines, Inc. | $8,777 |
| E.r. Squibb & Sons, L.l.c. | $8,223 |
| GlaxoSmithKline, LLC. | $6,720 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,406 |
| Amgen Inc. | $1,740 |
| Novartis Pharmaceuticals Corporation | $1,323 |
| Compensation for services other than consulting (speaking, faculty) | $52,800 |
|---|---|
| Consulting Fee | $28,678 |
| Travel and Lodging | $13,966 |
| Food and Beverage | $8,752 |
| Honoraria | $600 |
| Education | $213 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB, Inc. Sep 9, 2025 | Consulting Fee Bimzelx · Immunology | $7,980 |
| Tonix Medicines, Inc. May 17, 2025 | Consulting Fee | $7,800 |
| E.r. Squibb & Sons, L.l.c. Sep 12, 2025 | Consulting Fee | $5,525 |
| UCB, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $4,000 |
| AbbVie Inc. Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,850 |
| AbbVie Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,850 |
| AbbVie Inc. Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,300 |
| UCB, Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $3,000 |
| UCB, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $3,000 |
| AbbVie Inc. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $2,750 |
All 72 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,750 |
| Janssen Pharmaceuticals, Inc Dec 16, 2025 | Education TREMFYA · Immunology · in-kind | $13.17 |
| AbbVie Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $1,650 |
| GlaxoSmithKline, LLC. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $1,300 |
| AbbVie Inc. Dec 8, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to MANASSAS, VA · in-kind | $74.66 |
| AbbVie Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,650 |
| GlaxoSmithKline, LLC. Dec 1, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $1,300 |
| Amgen Inc. Nov 18, 2025 | Consulting Fee | $978 |
| AbbVie Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,650 |
| AbbVie Inc. Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,650 |
| UCB, Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $3,000 |
| GlaxoSmithKline, LLC. Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $1,300 |
| AbbVie Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,650 |
| GlaxoSmithKline, LLC. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $1,300 |
| Roche Products Limited Sep 26, 2025 | Travel and Lodging travel to Boston, MA | $407 |
| E.r. Squibb & Sons, L.l.c. Sep 12, 2025 | Consulting Fee | $5,525 |
| UCB, Inc. Sep 9, 2025 | Consulting Fee Bimzelx · Immunology | $7,980 |
| UCB, Inc. Sep 9, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Atlanta, GA | $64.40 |
| UCB, Inc. Sep 9, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Atlanta, GA | $24.00 |
| AbbVie Inc. Sep 8, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $550 |
| E.r. Squibb & Sons, L.l.c. Sep 6, 2025 | Travel and Lodging travel to Dallas, TX | $1,525 |
| E.r. Squibb & Sons, L.l.c. Sep 6, 2025 | Travel and Lodging travel to Dallas, TX | $464 |
| E.r. Squibb & Sons, L.l.c. Sep 5, 2025 | Travel and Lodging travel to Dallas, TX | $293 |
| GlaxoSmithKline, LLC. Aug 29, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $650 |
| UCB, Inc. Aug 22, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Atlanta, GA · in-kind | $497 |
| UCB, Inc. Aug 22, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Atlanta, GA · in-kind | $214 |
| UCB, Inc. Aug 22, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Atlanta, GA · in-kind | $92.30 |
| AbbVie Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $1,650 |
| Janssen Biotech, Inc. Aug 13, 2025 | Education TREMFYA · Immunology · in-kind | $99.99 |
| Eli Lilly and Company Jul 30, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,200 |
| AbbVie Inc. Jul 7, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $64.40 |
| AbbVie Inc. Jul 7, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $18.00 |
| AbbVie Inc. Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,300 |
| AbbVie Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,850 |
| AbbVie Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,650 |
| Grt US Holding, Inc. Jun 10, 2025 | Honoraria | $600 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $444 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $238 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $153 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to ROSEMONT, IL · in-kind | $40.00 |
| AbbVie Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $1,650 |
| AbbVie Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,650 |
| UCB, Inc. May 28, 2025 | Consulting Fee Bimzelx · Immunology | $1,425 |
| UCB, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $4,000 |
| UCB, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $3,000 |
| AbbVie Inc. May 22, 2025 | Travel and Lodging SKYRIZI · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $2,096 |
| AbbVie Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,650 |
| Tonix Medicines, Inc. May 17, 2025 | Consulting Fee | $7,800 |
| Tonix Medicines, Inc. May 17, 2025 | Travel and Lodging travel to CHICAGO, IL | $712 |
| Tonix Medicines, Inc. May 17, 2025 | Travel and Lodging travel to CHICAGO, IL | $215 |
| UCB, Inc. May 5, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Wexford, PA · in-kind | $945 |
| AbbVie Inc. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,650 |
| Janssen Biotech, Inc. Apr 4, 2025 | Education TREMFYA · Immunology · in-kind | $99.99 |
| Aurinia Pharma U.S., Inc. Mar 18, 2025 | Consulting Fee LUPKYNIS · LUPUS NEPHRITIS | $605 |
| AbbVie Inc. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $2,750 |
| AbbVie Inc. Mar 14, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $825 |
| UCB, Inc. Mar 7, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Wexford, PA · in-kind | $40.00 |
| AbbVie Inc. Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,850 |
| GlaxoSmithKline, LLC. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) BENLYSTA · IMMUNOLOGY | $650 |
| AbbVie Inc. Feb 28, 2025 | Travel and Lodging travel to PHOENIX, AZ · in-kind | $495 |
| AbbVie Inc. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,650 |
| AbbVie Inc. Feb 18, 2025 | Travel and Lodging SKYRIZI · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $1,242 |
| Novartis Pharmaceuticals Corporation Feb 14, 2025 | Consulting Fee COSENTYX · Dermatology | $650 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 8, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $489 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 7, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $1,030 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 7, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $220 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 6, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 6, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $210 |
| AbbVie Inc. Feb 1, 2025 | Travel and Lodging travel to PHOENIX, AZ · in-kind | $537 |
| AbbVie Inc. Feb 1, 2025 | Travel and Lodging travel to PHOENIX, AZ · in-kind | $483 |
| AbbVie Inc. Feb 1, 2025 | Travel and Lodging travel to PHOENIX, AZ · in-kind | $407 |
| UCB, Inc. Jan 7, 2025 | Consulting Fee Bimzelx · Immunology | $1,140 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 50 industry-funded studies in 2025, from 15 companies. The companies reported $5,331,989 in research payments for these studies, mostly to the institutions running them.
- A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment
Novartis Pharmaceuticals Corporation - A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06299098 - A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Eli Lilly and Company · Active, not recruiting · NCT06859268 - A phase 3 multicenter placebocontrolled randomized observerblinded trial to evaluate the efficacy safety tolerability immunogenicity and lot consistency of a 6VALENT ospabased lyme disease vaccine in healthy participa…
Pfizer Inc. - A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participan…
Novartis Pharmaceuticals Corporation - A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929066 - A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly and Company · Active, not recruiting · NCT07035093 - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588296
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.